Copp comes to the company from McKinsey & Co.
Ceribell announced that it has named Joshua Copp as its new chief operating officer.
In a press release, Ceribell co-founder and CEO Jane Chao, PhD, said, “Joshua's leadership within McKinsey & Co.'s Medical Device Division provides him with a wealth of expertise that he will now bring to our team. His professional experience driving growth and shaping markets with clients aligns seamlessly with Ceribell's vision to make Ceribell the standard of care in seizure management."
Ceribell developed an AI-powered point-of-care EEG diagnostic system and is working to improve seizure management in acute care.
"Ceribell stands at the forefront of medical technology, reshaping the landscape of neurodiagnostics," said Joshua Copp in the press release. "I look forward to working alongside this innovative team to enable hospitals to optimize workflows and save lives."
(Oct. 2, 2023); Ceribell Inc.; Ceribell Appoints Joshua Copp as Chief Operating Officer; https://www.prnewswire.com/news-releases/ceribell-appoints-joshua-copp-as-chief-operating-officer-301943415.html
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.